Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 7/20 | 0.33 |
| ▸ | VNN1 | O95497 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32661546 | 0.85 | ACACB (0.37) | EZH2ACACBVNN1PTK2BRAF | |
| SCHEMBL30768170 | 0.85 | MEN1 (0.38) | EZH2ACACBVNN1PTK2BRAF | |
| SCHEMBL29137741 | 0.78 | EZH2 (0.38) | EZH2LRRK2VNN1BRAF | |
| SCHEMBL29137743 | 0.78 | EZH2 (0.39) | EZH2LRRK2VNN1BRAF | |
| SCHEMBL23169376 | 0.71 | EZH2 (1.00) | EZH2CDK9ACACBVNN1 | |
| SCHEMBL23169377 | 0.71 | EZH2 (1.00) | EZH2CDK9ACACBVNN1 | |
| SCHEMBL28775793 | 0.71 | EZH2 (1.00) | EZH2CDK9ACACBVNN1 | |
| SCHEMBL23169378 | 0.71 | EZH2 (1.00) | EZH2CDK9ACACBVNN1 | |
| SCHEMBL28775792 | 0.71 | EZH2 (1.00) | EZH2CDK9ACACBVNN1 | |
| SCHEMBL28775794 | 0.71 | EZH2 (1.00) | EZH2CDK9ACACBVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| CN-117384153-A | Methyltransferase inhibitors and uses thereof | 上海赛岚生物科技有限公司 | 2024-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | EZH2, DOT1L, EHMT1 | EZH2 1/4885LRRK2 567/4885CDK2 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.